CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1ZST.TO 0.01HSAV.TO -0.03HSUV.U.TO 0.03
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
DON'T BUY

Pfizer Inc(PFE)

Nov 23, 2004
A very good company, but the recent problems with Bayer's similar drugs has him scared.
Photo of Neil WickhamNeil Wickham
No
Unlock Rating
$26.90

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 18, 2004
Offers reasonable opportunity here, but could be a long go before there are signs of recovery. Cheap. Long term concern is possible pricing controls.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$27.77

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 11, 2004
The big block buster drugs are starting to face generic competition. Very cheap, but the market is worried about nothing being on the horizon for 2005/2006. Under $30 is a good price. Be willing to sit and wait. A great story.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$27.15

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 11, 2004
Trading close to a 52 week low. Trading at about 11.5 X next year's earnings. A contrarian pick when looked at with the US$. A first class company. Have about $20 billion in net free cash flow.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$27.15

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 10, 2004
Stock has been extremely disappointing. Has the best fundamentals of all the drug stocks except for J & J. Drug sector has come under a number of significant pressures.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$27.47

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 02, 2004
An excellent company, but a poor stock. The whole pharmaceutical sector has been under pressure for 2/3 years.
Photo of Ian NakamotoIan Nakamoto
Owned
Unlock Rating
$28.70

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 29, 2004
SHould do well if Bush wins the election.
Photo of Alison DeansAlison DeansUnlock Rating
$28.95

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 27, 2004
Pharmaceuticals are cheaper than he has ever seen them. Cheap. Trading at low multiples.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$29.04

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 26, 2004
30% discount between their model price and current stock price.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$28.33

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 22, 2004
Has been beaten up. Has all the good things going for it according to analysts. Strong cash flow.
Photo of Robert StovallRobert Stovall
Owned
Unlock Rating
$27.74

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 20, 2004
Has had a very disappointing performance. Big pharmas have some issues facing them with regards to generic drugs. An extremely good company. Ran into problems because of their recall of Vioxx.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$28.30

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 12, 2004
Has dropped in sympathy with Merk and their recall of Vioxx as they have a similar product which is a big seller. Pharmaceutical industry as a whole has been hurt by generics and lagging R&D. Could drop further. All money is made in the US.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$29.86

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 07, 2004
Thinks its been oversold. Big pharmas have been in the dog house for at least 5 years.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$29.99

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 01, 2004
Interested in companies that have very good earnings growth and visibility. Have a pipeline that is not being valued appropriately.
Photo of Mary FarrellMary Farrell
Owned
Unlock Rating
$30.97

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 24, 2004
Best value in the market is in quality names. Best pharmaceutical company in the world. Just hasn't gone anywhere. New products are going into the pipeline.
Photo of Nicholas SargenNicholas Sargen
Owned
Unlock Rating
$29.66

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 706 to 720 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

BUG 4.27$44.31
GS -40.73$988.45
NFLX 2.92$80.32
DAL -0.11$79.8
DML.TO -0.16$4.03
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

CP.TO 1.15$124.99
VRT -19.67$237.39
NVDA -7.33$210.96
TSM -15.23$418.01
JPM -6.1$350.13

Popular Articles

Latest Sell Signals

AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79
ORCL -5.49$144.79

Most Recent Experts

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like